ADVI Health and Sheridan Capital Partners today announced that Sheridan has taken an ownership stake in ADVI. Together, the companies aim to accelerate, strengthen, and extend ADVI’s position as an established market access, commercialization, and policy firm through the expansion of its solutions and product offerings. Sheridan invested alongside ADVI senior leaders, who retained a meaningful ownership stake in the business and will remain active in the leadership and operations of the

Read more...

If You Purchased, Paid for, or Provided Reimbursement for the Alzheimer’s Disease Drug Namenda XR or Namenda IR and its AB-rated generic equivalents, between April 14, 2010 through December 31, 2017 (the estimated date that the anticompetitive effects of Generic Defendants’ unlawful conduct ceased), You Could Get Money from a Class Action Settlement.For more detailed information, visit: www.InReNamendaIndirectAntitrustLitigation.com To g

Read more...

Botanical Solution Inc.innovator of sustainable, consistent and cost-effective Advanced Botanical Materials for agricultural and pharmaceutical applications, has entered into a Partnership Agreement with Croda Pharma to build a robust, scalable and truly sustainable supply chain and deliver kilogram-quantities of QS-21 to the pharmaceutical industry.BSI and Croda Pharma are announcing this Partnership Agreement at the World Vaccine and Immunotherapy Congress West Coast 2022 in San Diego this

Read more...

ERS Genomics Limited is pleased to announce a new license agreement with Cosmo Bio. This is a non-exclusive license agreement granting Japan's Cosmo Bio access to the ERS CRISPR/Cas9 patent portfolio. ERS, co-founded by Dr. Emmanuelle Charpentier, 2020 Nobel Prize winner for gene-editing, provides access to the foundational CRISPR/Cas9 intellectual property. Over 100 patents are held worldwide.Eric Rhodes, CEO at ERS had the following statement: "CRISPR/Cas

Read more...

WuXi STA, a subsidiary of WuXi AppTec, today announced a new parenteral formulation manufacturing line has started operation at the drug product site in Wuxi city, China. It is the second line opened this year for parenteral drug product clinical and commercial manufacturing, with an annual capacity of 10 million units. This expansion demonstrates the company’s continuous commitment to enhance its injectable drug product platform. This new line features a fully automatic vial

Read more...

JB Pharma, one of the fastest growing pharmaceutical companies in India, today, has announced that it has received final approval from USFDA for its Abbreviated New Drug Application (ANDA), Venlafaxine Extended Release Tablets 37.5 mg, 75 mg, 150 mg and 225 mg. This product is based on OROS (Osmotic Controlled Release Oral Delivery System) technology, an advanced and precision controlled release mechanism – an area where JB has seen success with 3 products already in the US ma

Read more...

Focused on demonstrating a new shape of the pharmaceutical manufacturing in the post COVID era, CPHI & PMEC India 2022, organized by Informa Markets in India, commenced today at the India Expo Centre, Greater Noida, Delhi – NCR. The co-located shows provided a unique opportunity to all the stakeholders to discuss the entire range of pharma machinery, analytical instruments, laboratory technologies and equipment’s, ancillaries, ingredients and more in a hybrid format.

Read more...

TrialSpark announced today the formation of Libertas Bio following the acquisition of a majority position in a portfolio of immunodermatology assets from Asana BioSciences. The Libertas Bio pipeline now includes global rights to gusacitinib, an oral Phase 3-ready dual JAK/SYK inhibitor in development for chronic hand eczema, and ASN008, a Phase 2-ready topical sodium channel blocker in development for pruritus associated with atopic dermatitis. Libertas Bio will continue the development of th

Read more...